Published in Hepatitis Weekly, November 15th, 2004
"This study aimed to find how ribavirin increases viral disappearance in patients with hepatitis C virus (HCV) of genotype 1 and high baseline viral loads (>5.0 x105 copies/mL) when given with interferon (IFN). Using the real-time quantitative polymerase chain reaction, we measured serum HCV in 20 patients during the first 12 weeks of therapy with IFN-alpha2b and ribavirin. Controls were 10 similar patients given IFN-alpha2b alone," researchers in Japan report.
"IFN-alpha2b was given at 6 MU daily for 2 weeks, and then 3 times weekly. Ribavirin was given at 600 or 800 mg daily....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.